|
Lacarya Scott is an independent partner of Garrison Fathom for private equity transactions and is a seasoned investment professional with extensive experience in mergers and acquisitions, hedge fund investing, and corporate strategy.
He began his career at Life Technologies (formerly Invitrogen Corporation) as an associate in the M&A group, where he played a pivotal role in deals totaling $1.5 billion. His responsibilities spanned the entire transaction lifecycle, from target selection and financial valuation to presenting transactions for board approval. Following his tenure at Life Technologies, Lacarya joined Caxton Associates, a $15 billion global macro and sectorial hedge fund, where he invested in both public and private biotechnology companies. He served on multiple boards and orchestrated strategic exits, including the $525 million sale of GeminX to Cephalon, which delivered a 4x return over three years. Lacarya went on to hold key roles at Jermyn Street Capital and Ferghana Partners, as well as serving as Vice President of Business Development and Corporate Strategy for several private and public life science companies, including Mesoblast. In addition to his industry expertise, Lacarya has a strong academic foundation in biophysics and biotechnology. His research at New York University focused on:
Education & Certifications
|